Allogeneic hematopoietic stem cell transplantation (SCT) is often the only curative option for many patients with malignant and\nbenign hematological stem cell disorders. However, some issues are still of concern regarding finding a donor like shrinking\nfamily sizes in many societies, underrepresentation of the ethnic minorities in the registries, genetic variability for some races,\nand significant delays in obtaining stem cells after starting the search. So there is a considerable need to develop alternate donor\nstem cell sources. The rapid and near universal availability of the haploidentical donor is an advantage of the haploidentical\nSCT and an opportunity that is being explored currently in many centers especially using T cell replete graft and posttransplant\ncyclophosphamide. This is probably because it does not require expertise in graft manipulation and because of the lower costs.\nHowever, there are still lots of unanswered questions, like the effect of use of bone marrow versus peripheral blood as the source\nof stem cells on graft-versus-host disease, graft versus tumor, overall survival, immune reconstitution, and quality of life. Here we\nreview the available publications on bone marrow and peripheral blood experience in the haploidentical SCT setting.
Loading....